[go: up one dir, main page]

IL133136A0 - Use of leptin antagonists for the treatment of diabetes - Google Patents

Use of leptin antagonists for the treatment of diabetes

Info

Publication number
IL133136A0
IL133136A0 IL13313697A IL13313697A IL133136A0 IL 133136 A0 IL133136 A0 IL 133136A0 IL 13313697 A IL13313697 A IL 13313697A IL 13313697 A IL13313697 A IL 13313697A IL 133136 A0 IL133136 A0 IL 133136A0
Authority
IL
Israel
Prior art keywords
diabetes
treatment
leptin antagonists
leptin
antagonists
Prior art date
Application number
IL13313697A
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of IL133136A0 publication Critical patent/IL133136A0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2264Obesity-gene products, e.g. leptin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL13313697A 1997-06-06 1997-06-06 Use of leptin antagonists for the treatment of diabetes IL133136A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1997/002240 WO1998055139A1 (en) 1997-06-06 1997-06-06 Use of leptin antagonists for the treatment of diabetes

Publications (1)

Publication Number Publication Date
IL133136A0 true IL133136A0 (en) 2001-03-19

Family

ID=8166613

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13313697A IL133136A0 (en) 1997-06-06 1997-06-06 Use of leptin antagonists for the treatment of diabetes

Country Status (9)

Country Link
EP (1) EP0986397A1 (en)
JP (1) JP2002504102A (en)
KR (1) KR20010013414A (en)
AU (1) AU2951797A (en)
CA (1) CA2293504A1 (en)
HU (1) HUP0003428A3 (en)
IL (1) IL133136A0 (en)
TR (1) TR199902980T2 (en)
WO (1) WO1998055139A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777388B1 (en) 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
US7208572B2 (en) 1998-08-21 2007-04-24 Albany Medical College Leptin-related peptides
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
EP2417980A1 (en) 2004-02-11 2012-02-15 Amylin Pharmaceuticals Inc. Hybrid polypeptides with selectable properties
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
WO2006086769A2 (en) 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
EP2330125A3 (en) 2005-08-11 2012-12-12 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
EP2330124B1 (en) 2005-08-11 2015-02-25 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
WO2010118384A2 (en) 2009-04-10 2010-10-14 Amylin Pharmaceuticals, Inc. Amylin agonist compounds for estrogen-deficient mammals
EA024507B1 (en) 2010-09-28 2016-09-30 Амилин Фармасьютикалс, Ллк Highly soluble leptins
DK2729160T3 (en) 2011-07-08 2019-07-01 Aegerion Pharmaceuticals Inc MANIPULATED POLYPEPTIDES WHICH HAVE IMPROVED EFFECT TIME AND REDUCED IMMUNOGENICITY
EP3434268B1 (en) 2012-09-27 2022-04-20 The Children's Medical Center Corporation Compounds for the treatment of obesity and methods of use thereof
TR201901299T4 (en) 2013-11-26 2019-02-21 Childrens Medical Ct Corp Compounds for obesity treatment and methods of their use.
WO2015153933A1 (en) 2014-04-03 2015-10-08 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
EP3509624B1 (en) 2016-09-12 2023-08-09 Amryt Pharmaceuticals Inc. Methods of detecting anti-leptin neutralizing antibodies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
IL122718A0 (en) * 1995-06-30 1998-08-16 Lilly Co Eli Methods for treating diabetes

Also Published As

Publication number Publication date
WO1998055139A1 (en) 1998-12-10
CA2293504A1 (en) 1998-12-10
KR20010013414A (en) 2001-02-26
AU2951797A (en) 1998-12-21
JP2002504102A (en) 2002-02-05
HUP0003428A2 (en) 2001-05-28
HUP0003428A3 (en) 2001-12-28
TR199902980T2 (en) 2000-05-22
EP0986397A1 (en) 2000-03-22

Similar Documents

Publication Publication Date Title
IL130027A (en) Rosiglitazone - glyburide synergistic combinations for treatment of diabetes
HUP0003428A3 (en) Use of leptin antagonists for the treatment of diabetes
HUP0002030A3 (en) Use of glur5 receptorantagonists for the treatment of pain
GB9824160D0 (en) Heterocyclic compounds and their therapeutic use
IL130831A0 (en) Imino-aza-anthracylinone derivatives for the treatment of amyloidosis
GB9810920D0 (en) Therapeutic use
GB9816897D0 (en) Therapeutic use
GB9812662D0 (en) Therapeutic use
GB9726223D0 (en) The treatment of materials
HK1027742A (en) Use of leptin antagonists for the treatment of diabetes
PT1011678E (en) Use of mecamylamine for the treatment of nicotine-responsive neuropsychiatric disorders
NO995940D0 (en) Use of leptin antagonists for the treatment of diabetes
GB9811624D0 (en) Therapeutic use
GB9821179D0 (en) Therapeutic use
GB9812664D0 (en) Therapeutic use
PL337220A1 (en) Application of leptin antagonists in treating diabetes
GB9618290D0 (en) Treatment of diabetes
GB9820768D0 (en) Heterocyclic compounds and their therapeutic use
GB9819505D0 (en) Heterocyclic compounds and their therapeutic use
GB9714742D0 (en) Medical cement
GB9713240D0 (en) Heterocyclic compounds and their therapeutic use
GB9802622D0 (en) Compounds and their therapeutic use
GB9812314D0 (en) Treatment of diabetes
GB9815149D0 (en) Treatment of diabetes
GB9812618D0 (en) Therapeutic use